Physician profile
Deepa Sharma
NPI 1457519001
$1,957.06
in general payments reported to CMS, 2019-2025
19 companies · $161 in 2025
The $161 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2020: $16.47 · 2023: $1,161 · 2024: $479 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,700 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,700.18 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $506.24 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $207.87 | 2023-2024 | Arexvy, Shingrix |
| Pfizer INC. | $173.49 | 2023-2024 | |
| Dexcom, INC. | $172.49 | 2023-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Astellas Pharma US INC | $157.99 | 2023-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $148.17 | 2023 | |
| Exact Sciences Corporation | $119.60 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Tandem Diabetes Care, INC. | $104.91 | 2023-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Lilly USA, LLC | $74.22 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Insulet Corporation | $56.67 | 2024-2025 | Omnipod |
| Abbvie INC. | $47.26 | 2023-2024 | Ubrelvy |
| Xeris Pharmaceuticals, INC. | $37.22 | 2024-2025 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $31.42 | 2020-2023 | |
| Cardiovascular Systems INC. | $26.88 | 2019 | |
| Sumitomo Pharma America, INC. | $24.91 | 2025 | Gemtesa |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $19.47 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.96 | 2024 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals LP | $17.00 | 2024 | Farxiga |
| Amarin Pharma, INC. | $13.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepa Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.